Johnson & Johnson

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

15 Jan 2025

Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

13 Jan 2025

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizo

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

10 Jan 2025

The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter offers electrophysiologists the ability to switch between radiofrequency and pulsed field energy in a single, fully integrated catheter CE Mark suppo

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

09 Jan 2025

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

09 Jan 2025

Learn how an analytical microbiologist and her team are advancing self-sterilizing surgical instruments and medical device design with a digital app.

Johnson & Johnson Statement on VARIPULSE™ U.S. External Evaluation

09 Jan 2025

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

08 Jan 2025

Building on decades of the Company’s Alzheimer’s research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J’s com

What is lupus?

03 Jan 2025

Lupus is a chronic autoimmune disease where the immune system attacks the body. Learn how Johnson & Johnson advances lupus treatments and deepens understanding for all.

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025

02 Jan 2025

Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis

26 Dec 2024

The Company is licensing a STAT6 program from Kaken Pharmaceutical that targets a clinically relevant pathway in atopic dermatitis as well as other autoimmune and allergic diseases The agreement bolst

View details about the software product Informachine News Trackers